Malignant solid tumors: Patients with relapsed or refractory, advanced and/or metastatic melanoma, Non-Small Cell Lung Cancer (NSCLC), Head and neck squamous cell carcinoma (HNSCC), Panctreatic ductal adenocarcinoma (PDAC) or Colorectal Cancer (CRC).

• GEN1042 Trial of Safety and Anti-tumor Activity in Subjects with Malignant Solid Tumors Recruitment ended
  2023-508526-10-00 7 2019-10-01

Showing 1–1 of 1 trials